✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Gilead Sciences, Inc

Common Name
Gilead Sciences
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17,000
Ticker
GILD
Exchange
Nasdaq
Description
Gilead Sciences Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious and life-threatening diseases. The company’s core fr...

Gilead Sciences's GHG Emissions Data Preview

In 2024, Gilead Sciences completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Gilead Sciences has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2024202320222021-2019
Total Scope 1
53,856a
56,435a
55,919b
Total Scope 2
Market-Based
17,137a
22,603a
26,291b
Location-Based
45,680a
54,180a
57,255b
Total Scope 3
998,100a
1,146,141a
145,858b
Total Scope 1 Revenue Intensity (tCO2e/$M)
1.873a
2.0812a
2.0497b
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=GILD&reporting_period=2024"

Verified Sources Behind Gilead Sciences’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Gilead Sciences's Verification report 2024
b. Gilead Sciences's Verification report 2023
c. Gilead Sciences's Verification report 2021

Insights into Gilead Sciences's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Gilead Sciences amounted to 99,536 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Gilead Sciences decreased by 10.02%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Gilead Sciences's Scope 1 Emissions Over Time

201920202021202220232024015 k30 k45 k60 ktCO2e-11%+13%+2%+1%-5%
  • Total Scope 1
  • Year-over-Year Change

What are Gilead Sciences's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Gilead Sciences were 53,856 metric tons of CO₂ equivalent (tCO₂e).a

Has Gilead Sciences reduced its Scope 1 emissions over time?

Since 2019, Gilead Sciences's Scope 1 emissions have remained relatively, stable, indicating that Gilead Sciences's emissions have plateaued with no significant change in its operational footprint.ac

Compared to the previous year (2023), Gilead Sciences's Scope 1 emissions decreased by 4.57%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Gilead Sciences's Scope 2 emissions?

In 2024, Gilead Sciences reported Scope 2 greenhouse gas (GHG) emissions of 17,137 tCO₂e using the market-based method and 45,680 tCO₂e using the location-based method.a

Has Gilead Sciences reduced its Scope 2 emissions over time?

Since 2019, Gilead Sciences's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have decreased by 17.25%, reflecting a declining long-term trend in Scope 2 emissions over time.ac

Compared to the previous year (2023), Gilead Sciences's Scope 2 emissions (Location-Based) fell by 15.69% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a

What methodology does Gilead Sciences use for Scope 2 reporting?

In 2024, Gilead Sciences reported its Scope 2 emissions using the market-based method and using the location-based method.a

Gilead Sciences's Scope 2 Emissions Over Time

201920202021202220232024015 k30 k45 k60 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Gilead Sciences's Value Chain Emissions

In 2024, Gilead Sciences reported 998,100 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Gilead Sciences includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Gilead Sciences's Scope 3 Emissions Over Time

2019202020212022202320240300 k600 k900 k1.2 MtCO2e-60%+283%+47%+686%-13%
  • Total Scope 3
  • Year-over-Year Change

What are Gilead Sciences's Scope 3 emissions?

In 2024, Gilead Sciences reported total Scope 3 emissions of 998,100 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 96.09% of these emissions originated from upstream activities such as purchased goods and capital goods, while 3.91% came from downstream activities like product use, distribution, and end-of-life treatment.a

Has Gilead Sciences reduced its Scope 3 emissions over time?

Since 2019, Gilead Sciences's Scope 3 emissions have increased by 1,445.05%, reflecting a rising long-term trend in Scope 3 emissions over time.ac

Compared to the previous year (2023), Gilead Sciences's Scope 3 emissions decreased by 12.92%, highlighting the company's efforts to lower indirect emissions from its value chain.a

What categories of Scope 3 emissions does Gilead Sciences disclose?

In 2024, Gilead Sciences reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This reflects a high level of granularity and transparency in the company's emissions reporting.

What are the main sources of Gilead Sciences's Scope 3 emissions?

In 2024, the largest contributors to Gilead Sciences's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 731,443 tCO₂e (73.28%)
  • Upstream Transportation and Distribution (Cat. 4): 70,029 tCO₂e (7.02%)
  • Business Travel (Cat. 6): 65,263 tCO₂e (6.54%)

Gilead Sciences's Scope 3 Emissions by Categories

Business Travel(Cat. 6)(6.5%)Purchased Goods andServices (Cat. 1)(73.3%)UpstreamTransportation andDistribution(Cat. 4)(7.0%)

Insights into Gilead Sciences’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Gilead Sciences reported Scope 1 greenhouse gas (GHG) emissions of 53,856 tCO₂e and total revenues of USD 28,754 millions. This translates into an emissions intensity of 1.87 tCO₂e per millions USD.a

Gilead Sciences's Scope 1 Emissions Intensity Compared to Peers

5005,00050,000500,00010,000,000Scope 1 Emissions (tCO2e)2002,00010,00050,000200,000Revenues (Millions of USD)Orion OyjYear: 2025Scope 1: 5,018 tCO2eRevenue: $M 2,221Scope 1 Intensity: 2.26 tCO2e/$MCspc Pharmaceutical GroupYear: 2024Scope 1: 474,567 tCO2eRevenue: $M 3,975Scope 1 Intensity: 119.39 tCO2e/$MRecordatiYear: 2025Scope 1: 36,557 tCO2eRevenue: $M 3,078Scope 1 Intensity: 11.88 tCO2e/$MZhangzhou Pientzehuang PharmaceuticalYear: 2023Scope 1: 2,301 tCO2eRevenue: $M 1,415Scope 1 Intensity: 1.63 tCO2e/$MAstellas PharmaYear: 2024Scope 1: 52,212 tCO2eRevenue: $M 10,589Scope 1 Intensity: 4.93 tCO2e/$MDaiichi SankyoYear: 2024Scope 1: 91,836 tCO2eRevenue: $M 10,576Scope 1 Intensity: 8.68 tCO2e/$MBayerYear: 2025Scope 1: 1,890,000 tCO2eRevenue: $M 53,581Scope 1 Intensity: 35.27 tCO2e/$MStrykerYear: 2023Scope 1: 54,854 tCO2eRevenue: $M 20,498Scope 1 Intensity: 2.68 tCO2e/$MDanaherYear: 2024Scope 1: 109,046 tCO2eRevenue: $M 23,875Scope 1 Intensity: 4.57 tCO2e/$MNovo NordiskYear: 2025Scope 1: 120,000 tCO2eRevenue: $M 48,646Scope 1 Intensity: 2.47 tCO2e/$MAstraZenecaYear: 2024Scope 1: 125,386 tCO2eRevenue: $M 54,074Scope 1 Intensity: 2.32 tCO2e/$MNovartisYear: 2024Scope 1: 207,000 tCO2eRevenue: $M 40,180Scope 1 Intensity: 5.15 tCO2e/$MRoche HoldingYear: 2025Scope 1: 211,962 tCO2eRevenue: $M 79,968Scope 1 Intensity: 2.65 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MOtsuka HoldingsYear: 2024Scope 1: 368,733 tCO2eRevenue: $M 14,840Scope 1 Intensity: 24.85 tCO2e/$MGSKYear: 2024Scope 1: 521,000 tCO2eRevenue: $M 39,374Scope 1 Intensity: 13.23 tCO2e/$MOrganon & CoYear: 2024Scope 1: 34,200 tCO2eRevenue: $M 6,403Scope 1 Intensity: 5.34 tCO2e/$MBiogenYear: 2024Scope 1: 56,611 tCO2eRevenue: $M 9,676Scope 1 Intensity: 5.85 tCO2e/$MMerck & Co IncYear: 2024Scope 1: 721,200 tCO2eRevenue: $M 64,168Scope 1 Intensity: 11.24 tCO2e/$MAbbvieYear: 2025Scope 1: 304,649 tCO2eRevenue: $M 61,160Scope 1 Intensity: 4.98 tCO2e/$MJohnson & JohnsonYear: 2024Scope 1: 314,690 tCO2eRevenue: $M 88,820Scope 1 Intensity: 3.54 tCO2e/$MEli Lilly and CoYear: 2024Scope 1: 192,000 tCO2eRevenue: $M 45,043Scope 1 Intensity: 4.26 tCO2e/$MBristol-Myers SquibbYear: 2024Scope 1: 206,726 tCO2eRevenue: $M 48,300Scope 1 Intensity: 4.28 tCO2e/$MPfizerYear: 2024Scope 1: 613,218 tCO2eRevenue: $M 63,627Scope 1 Intensity: 9.64 tCO2e/$MAmgenYear: 2024Scope 1: 147,000 tCO2eRevenue: $M 33,424Scope 1 Intensity: 4.40 tCO2e/$MGilead SciencesYear: 2024Scope 1: 53,856 tCO2eRevenue: $M 28,754Scope 1 Intensity: 1.87 tCO2e/$M

How does Gilead Sciences's GHG emissions intensity compare to its peers?

In 2024, Gilead Sciences reported a Scope 1 emissions intensity of 1.87 tCO₂e per millions USD. Compared to the peer group median of 4.98, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Gilead Sciences rank on GHG emissions intensity within its industry?

In 2024, Gilead Sciences ranked 2 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Gilead Sciences among the top performers, with one of the lowest emissions intensities relative to peers.a

Insights into Gilead Sciences's Total Carbon Footprint

In 2024, Gilead Sciences reported a total carbon footprint of 1,097,636 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 12.66% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a

The largest contributor to Gilead Sciences's total carbon footprint was Scope 3 emissions, accounting for 90.93% of the company's total carbon footprint, followed by Scope 1 emissions at 4.91%.a

Want Full Access to Gilead Sciences's GHG Emissions Dataset?
Start 30-Day Free Trial